Zobrazeno 1 - 10
of 17
pro vyhledávání: '"S D, Mikolajczyk"'
Autor:
D. Echtle, F. Moll, S. D. Mikolajczyk, M. S. Michel, B. Wullich, J. Hartmann, L. Blair Shamel, H. G. Rittenhouse, Axel Semjonow, G. de Angelis, P. Rathert
Publikováno v:
Urologie in Deutschland ISBN: 9783540310341
Urologie in Deutschland
Urologie in Deutschland
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cfb7e6aed281f26aa3bc5a7815661f6c
https://doi.org/10.1007/978-3-540-31035-8_39
https://doi.org/10.1007/978-3-540-31035-8_39
Autor:
S D, Mikolajczyk, K M, Marker, L S, Millar, A, Kumar, M S, Saedi, J K, Payne, C L, Evans, C L, Gasior, H J, Linton, P, Carpenter, H G, Rittenhouse
Publikováno v:
Cancer research. 61(18)
Prostate-specific antigen (PSA) is a widely used serum marker for prostate cancer (PCa) but has limited specificity for distinguishing early PCa from benign prostatic hyperplasia, because both PCa and benign prostatic hyperplasia release PSA into the
Autor:
J A, Finlay, J R, Day, C L, Evans, R, Carlson, K, Kuus-Reichel, L S, Millar, S D, Mikolajczyk, M, Goodmanson, G G, Klee, H G, Rittenhouse
Publikováno v:
Clinical chemistry. 47(7)
Human kallikrein 2 (hK2) shares 80% sequence identity with prostate-specific antigen (PSA). Because both hK2 and hK2-alpha(1)-antichymotrypsin (hK2-ACT) complexes have been identified in patient sera, we devised an immunoassay for total hK2 [(thK2);
Autor:
S D, Mikolajczyk, L S, Millar, K M, Marker, T J, Wang, H G, Rittenhouse, L S, Marks, K M, Slawin
Publikováno v:
The Prostate. 45(3)
We previously reported that levels of BPSA, a modified form of prostate-specific antigen (PSA), are significantly elevated in prostate transition-zone tissue exhibiting nodular hyperplastic changes associated with the presence of benign prostatic hyp
Publikováno v:
The Prostate. 44(3)
Human prostate-specific antigen (PSA) and human kallikrein 2 (hK2) are expressed primarily by prostate epithelial cells. PSA and hK2 both exist as free protein and complexed with protease inhibitors (e.g., alpha1-antichymotrypsin, ACT) in serum. The
Publikováno v:
European journal of biochemistry. 267(13)
We previously identified a modified molecular form of prostate-specific antigen that is significantly elevated in the nodular transition zone tissue of prostates with benign prostatic hyperplasia. This prostate-specific antigen form, designated BPSA,
Autor:
S D, Mikolajczyk, L S, Millar, T J, Wang, H G, Rittenhouse, L S, Marks, W, Song, T M, Wheeler, K M, Slawin
Publikováno v:
Cancer research. 60(3)
Prostate-specific antigen (PSA) is a widely used serum marker for prostate cancer (PCa), but in the critical diagnostic range of 4-10 ng/ml it has limited specificity for distinguishing early PCa from benign prostatic hyperplasia (BPH). PSA in serum
Autor:
S D, Mikolajczyk, L S, Millar, K M, Marker, H G, Rittenhouse, R L, Wolfert, L S, Marks, M C, Charlesworth, D J, Tindall
Publikováno v:
Cancer research. 59(16)
Human kallikrein (hK) 2 is an arginine-selective serine protease expressed predominantly in the prostate that has an 80% sequence identity with prostate-specific antigen. Expression of hK2 is elevated in the tumor epithelium compared to benign prosta
Publikováno v:
International journal of cancer. 81(3)
Human kallikrein 2 (hK2) is a serine protease expressed predominantly in the prostate which has 80% homology to prostate-specific antigen (PSA). hK2 is an active trypsin-like protease which has been shown by immuno-histochemical staining to be more h
Autor:
M S, Saedi, T M, Hill, K, Kuus-Reichel, A, Kumar, J, Payne, S D, Mikolajczyk, R L, Wolfert, H G, Rittenhouse
Publikováno v:
Clinical chemistry. 44(10)
Prostate-specific antigen (PSA, hK3) is a diagnostic marker for prostatic cancer but lacks the specificity to sufficiently distinguish between prostatic cancer and benign prostatic hyperplasia (BPH). Human glandular kallikrein 2 (hK2) has been propos